NasdaqCM - Nasdaq Real Time Price USD

TuHURA Biosciences, Inc. (HURA)

Compare

4.1400

+0.0350

+(0.85%)

At close: 4:00:01 PM EDT

4.1400

0.00

(0.00%)

After hours: 4:05:10 PM EDT

HURA: 2024 Financial Results

By John Vandermosten, CFA NASDAQ:HURA READ THE FULL HURA RESEARCH REPORT Operational and Financial Results On April 1 st , 2025, TuHURA Biosciences, Inc. (NASDAQ:HURA) reported 2024 financial and operational results and filed its Form 10-K with the SEC. TuHURA provided updates on its Phase III trial in Merkel cell carcinoma (MCC), the acquisition of Kineta and introduced a new board member and

Zacks Small Cap Research 2 days ago

HURA
+0.85%
TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that an abstract highlighting Kineta Inc.'s novel KVA12123 antibody and an abstract from Moffitt Cancer Center scientists examining the mechanisms of Company's IFx-Hu2.0 therapy in advanced melanoma have been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, tak

PR Newswire 8 days ago

KANT

HURA
+0.85%
TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the appointment of Bertrand Le Bourdonnec, PhD as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management.

PR Newswire 9 days ago

HURA
+0.85%
Is TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 14 days ago

HURA
+0.85%
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided financial results for fiscal year 2024 and provided a corporate update.

PR Newswire 15 days ago

HURA
+0.85%
TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

Dr. Tendler oversaw 30 Major Drug Approvals, including worldwide approvals for J&J's transformational treatments in hematologic malignancies, prostate, lung and bladder cancers Dr. Tendler also oversaw 13 FDA Breakthrough Designations accelerating ...

ACCESS Newswire last month

HURA
+0.85%
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

Live webcast fireside chat on Tuesday, March 18th at 8:30 AM PT TAMPA, FL / ACCESS Newswire / March 10, 2025 /TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to ...

ACCESS Newswire last month

HURA
+0.85%
TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here TAMPA, FL / ACCESS Newswire / February 19, 2025 /TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance ...

ACCESS Newswire last month

HURA
+0.85%
HURA: Initiating an Immune Response

By John Vandermosten, CFA NASDAQ:HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation of $9.25 per share. This value is based on our estimates for successful development and commercialization of IFx-2.0 in patients with Merkel cell carcinoma (MCC) and KVA12 which will be advanced in acute myeloid leukemia (AML). IFx-2.0 is

Zacks Small Cap Research 2 months ago

HURA
+0.85%
When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)?

TuHURA Biosciences, Inc. ( NASDAQ:HURA ) is possibly approaching a major achievement in its business, so we would like...

Simply Wall St. 2 months ago

HURA
+0.85%
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kineta, Inc. (OTC PINK:KANT) ("Kineta"), a clinical-stage biotechnology ...

ACCESS Newswire 4 months ago

KANT

HURA
+0.85%
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

TuHURA Biosciences, Inc. (Nasdaq:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided a business update and outlined upcoming ...

ACCESS Newswire 4 months ago

HURA
+0.85%
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

TAMPA, FL / ACCESSWIRE / October 23, 2024 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today ...

ACCESS Newswire 5 months ago

HURA
+0.85%
TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

Live moderated webcast with Dr. Jim Bianco, President and Chief Executive Officer of TuHURA on Wednesday, October 30th at 4 PM ET TAMPA, FL / ACCESSWIRE / October 22, 2024 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase ...

ACCESS Newswire 5 months ago

HURA
+0.85%
TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Combined company will operate as TuHURA Biosciences, Inc. and advance pipeline of novel technologies to overcome resistance to cancer immunotherapy Lead program entering single Phase 3 accelerated approval registration trial in first half of 2025 ...

ACCESS Newswire 5 months ago

HURA
+0.85%

Performance Overview

Return	HURA	S&P 500 (^GSPC)
YTD	+1.22%	-10.30%
1-Year	+10.55%	+4.44%
3-Year	-99.26%	+20.10%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TuHURA Biosciences, Inc. (HURA)

HURA: 2024 Financial Results

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

Is TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans?

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

HURA: Initiating an Immune Response

When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)?

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Performance Overview